ReviewJournal of clinical medicine2025
Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Whole-Body PSMA-PET/CT dataset with manually annotated tumor lesions.Scientific data · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common cancer, affecting millions of men globally and having a significant burden on health care systems. During recent years, the rapid development of the nuclear medicine field and the wide use and application of positron emission tomography combined with computed tomography (PET/CT) have significantly changed the diagnosis, treatment approach and patient outcomes. Semiquantitative analysis in PET/CT imaging quantifies the load of the disease in patients diagnosed with prostate cancer without measuring the precise amount of a radiotracer injected into the patient; instead, there is an indirect evaluation of the radiotracer using semiquantitative indices. Beginning with the standard uptake value (SUV) in Fluorodeoxyglucose (FDG) PET/CT, various semiquantitative measures have been created and are now used for analyzing different radiotracers. The purpose of this review is to provide an overview of the importance of the semiquantitative analysis in PET/CT imaging with the use of prostate-specific radiotracers at the initial staging of prostate cancer, as well as in biochemical recurrence and in the metastatic state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.